These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38487923)

  • 1. The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma.
    Tavabie OD; Salehi S; Aluvihare VR
    Expert Opin Ther Targets; 2024 Mar; 28(3):179-191. PubMed ID: 38487923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma.
    Tavabie OD; Salehi S; Aluvihare VR
    Expert Rev Mol Diagn; 2024; 24(1-2):5-22. PubMed ID: 38059597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of microRNA-21-sponge and pre-microRNA-122 by MS2 virus-like particles to therapeutically target hepatocellular carcinoma cells.
    Zhang J; Li D; Zhang R; Peng R; Li J
    Exp Biol Med (Maywood); 2021 Dec; 246(23):2463-2472. PubMed ID: 34644206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs in the Occurrence and Development of Primary Hepatocellular Carcinoma.
    Xu J; Li J; Zheng TH; Bai L; Liu ZJ
    Adv Clin Exp Med; 2016; 25(5):971-975. PubMed ID: 28028963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma.
    Umeda S; Kanda M; Kodera Y
    Expert Rev Mol Diagn; 2019 Aug; 19(8):725-738. PubMed ID: 31248309
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.
    Zheng F; Liao YJ; Cai MY; Liu TH; Chen SP; Wu PH; Wu L; Bian XW; Guan XY; Zeng YX; Yuan YF; Kung HF; Xie D
    PLoS Genet; 2015 Feb; 11(2):e1004873. PubMed ID: 25693145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity.
    Xie QY; Almudevar A; Whitney-Miller CL; Barry CT; McCall MN
    BMC Med Genomics; 2016 Apr; 9():18. PubMed ID: 27059462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.
    Mohr R; Özdirik B; Lambrecht J; Demir M; Eschrich J; Geisler L; Hellberg T; Loosen SH; Luedde T; Tacke F; Hammerich L; Roderburg C
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.
    Li F; Wang F; Zhu C; Wei Q; Zhang T; Zhou YL
    Int J Nanomedicine; 2018; 13():2295-2307. PubMed ID: 29713162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [microRNA: new diagnostic and therapeutic tools in liver disease?].
    Gougelet A; Colnot S
    Med Sci (Paris); 2013 Oct; 29(10):861-7. PubMed ID: 24148124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A
    J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
    Wang Z; Zhang G; Wu J; Jia M
    Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
    Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
    Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.
    Vainshtein JM; Kabarriti R; Mehta KJ; Roy-Chowdhury J; Guha C
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):786-803. PubMed ID: 24969793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma.
    Yao M; Wang L; Qiu L; Qian Q; Yao D
    Anticancer Agents Med Chem; 2015; 15(4):453-60. PubMed ID: 25511513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.
    D'Anzeo M; Faloppi L; Scartozzi M; Giampieri R; Bianconi M; Del Prete M; Silvestris N; Cascinu S
    Molecules; 2014 May; 19(5):6393-406. PubMed ID: 24853455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.
    Lendvai G; Szekerczés T; Gyöngyösi B; Schlachter K; Kontsek E; Pesti A; Patonai A; Werling K; Kovalszky I; Schaff Z; Kiss A
    Pathol Oncol Res; 2019 Jul; 25(3):1103-1109. PubMed ID: 30411298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA involvement in hepatocellular carcinoma.
    Gramantieri L; Fornari F; Callegari E; Sabbioni S; Lanza G; Croce CM; Bolondi L; Negrini M
    J Cell Mol Med; 2008 Dec; 12(6A):2189-204. PubMed ID: 19120703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.
    Kanda T; Goto T; Hirotsu Y; Moriyama M; Omata M
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30889843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.